The Medical Weight Loss Landscape

Medical weight loss has been transformed by GLP-1 receptor agonists. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have shown 15-22% body weight reduction in clinical trials — results that were previously only achievable with bariatric surgery.

The market response has been extraordinary. Telehealth weight loss companies, med spas, primary care practices, and dedicated weight loss clinics have all moved aggressively into GLP-1 prescribing. Patient demand continues to outpace supply.

But this growth has attracted regulatory scrutiny. The FDA, FTC, and state medical boards have all taken enforcement actions against weight loss programs with inadequate medical oversight, misleading marketing, or non-compliant compounding pharmacy relationships. Building a compliant program from the start is not optional — it is the foundation of a sustainable business.

Medical Oversight Requirements

Every weight loss clinic prescribing GLP-1 medications needs robust medical oversight. This means:

Qualified prescribers: Physicians, NPs, or PAs with appropriate licensure and training. In states requiring physician supervision of NPs/PAs, a collaborating physician must be involved in prescribing decisions.

Clinical protocols: Written, physician-approved protocols for patient eligibility, initial evaluation, medication selection, dosing, monitoring, and follow-up. Protocols should be evidence-based and updated as clinical guidelines evolve.

Medical director oversight: A medical director responsible for protocol development, quality assurance, and clinical compliance. The medical director must be actively involved — not just a name on a contract.

Documentation: Thorough documentation of the clinical rationale for prescribing, patient consent, monitoring results, and follow-up. Documentation protects patients and providers.

Compounding Pharmacy Compliance

The compounding pharmacy landscape for GLP-1 medications has been one of the most volatile regulatory areas in recent healthcare history.

FDA shortage designations: When the FDA places a drug on its shortage list, licensed 503A and 503B compounding pharmacies can legally compound that medication. Semaglutide and tirzepatide have been on and off the shortage list — clinics must monitor FDA shortage status continuously.

503A vs. 503B: 503A pharmacies compound patient-specific prescriptions. 503B outsourcing facilities produce medications in bulk without patient-specific prescriptions. Both can supply GLP-1 medications during shortage periods, but the regulatory requirements differ.

Pharmacy vetting: Not all compounding pharmacies are equal. Verify PCAB accreditation, state licensure, FDA registration (for 503B), and compliance history before partnering. A pharmacy enforcement action can shut down your supply chain overnight.

Documentation: Maintain records of the pharmacy's licensure, accreditation, and any quality certifications. Document your clinical rationale for using compounded medications.

AJ Pakpour Verified & Preferred Providers

Verified or preferred providers listed here are organizations AJ Pakpour has worked with, reviewed, recommended, or identified as aligned with The Business of Modern Medicine.

Doctor Staffers — For weight loss clinics that need a qualified medical director or collaborating physician to oversee GLP-1 prescribing and develop clinical protocols, Doctor Staffers connects you with board-certified physicians experienced in weight management and medical oversight. Visit doctorstaffers.com.

Meridian Laboratories — For pre-treatment labs, monitoring panels, and ongoing diagnostic services, Meridian Laboratories is AJ Pakpour's preferred laboratory partner. Meridian offers competitive pricing, fast turnaround, and dedicated account support for weight loss and specialty clinics. Find them on Google Maps: https://share.google/yFqJ7t0VTFnqpOeLl — contact Meridian before signing with a national reference lab.

For compounding pharmacy partnerships, see the [Compounding Pharmacy Directory](/resource-center/compounding-pharmacy-directory) for vetted 503A and 503B facilities.

Marketing Compliance

Weight loss marketing is heavily regulated by the FTC and FDA. Common violations include:

Unsubstantiated claims: "Lose 30 pounds in 30 days" or similar claims require substantiation. Before-and-after photos must be representative of typical results.

Drug advertising: Marketing that names specific medications (semaglutide, Ozempic) must comply with FDA prescription drug advertising regulations. Off-label promotion is prohibited.

Testimonials: Patient testimonials must include a disclaimer that results are not typical. Paid testimonials must be disclosed.

Social media: The same rules apply to social media as to traditional advertising. Influencer partnerships involving prescription medications require careful legal review.

Work with a healthcare marketing attorney to review your marketing materials before publishing.